Milestone
The central milestone is full FDA approval in December 2025 for trastuzumab deruxtecan, or Enhertu, plus pertuzumab as first-line therapy for unresectable or metastatic HER2-positive adult breast cancer. This is not a marginal label broadening. It is the first time in more than a decade that a regimen has demonstrated superiority to the established THP standard in front-line HER2-positive metastatic disease, and it is arguably the clearest proof yet that an antibody-drug conjugate can graduate from later-line salvage into the first-line standard-setting position.
Disease context and remaining need
HER2-positive disease accounts for roughly 15% to 20% of breast cancers and is biologically aggressive, with a high risk of recurrence and metastasis if inadequately controlled. The earlier CLEOPATRA era transformed outcomes, but it did not eliminate unmet need. THP delivered a median progression-free survival of 18.7 months and median overall survival of 57.1 months in its original study, yet about half of patients still progressed within roughly 1.5 years and some real-world datasets showed a real-world PFS of only 13.57 months. In other words, HER2-positive metastatic breast cancer became treatable, not solved.
Mechanistic rationale
Enhertu's advance is rooted in more than target familiarity. The drug couples HER2 recognition to a cleavable linker and potent topoisomerase I inhibitor payload, enabling high drug-to-antibody ratio delivery and a bystander effect that may help address intratumoral heterogeneity. In the first-line setting, the addition of pertuzumab is mechanistically sensible rather than merely additive branding. Pertuzumab blocks a distinct HER2 dimerization interface, while trastuzumab deruxtecan delivers cytotoxic payload after HER2 binding and internalization.
Clinical evidence
The approval was based on the global phase III DESTINY-Breast09 trial, which compared trastuzumab deruxtecan with or without pertuzumab against standard THP in front-line HER2-positive advanced or metastatic breast cancer. The primary endpoint was blinded independent central review-assessed progression-free survival. Data presented at the 2025 ASCO meeting showed a median PFS of 40.7 months for trastuzumab deruxtecan plus pertuzumab versus 26.9 months for THP, corresponding to a 44% reduction in the risk of progression or death. Confirmed objective response rate was 85.1% versus 78.6%, and complete response rate was 15.1% versus 8.5%.
Safety and risk-benefit balance
The safety profile of trastuzumab deruxtecan plus pertuzumab was consistent with the known profiles of the constituent drugs and did not reveal new serious toxicities. That does not mean safety is trivial. Enhertu has always demanded careful attention to interstitial lung disease and other payload-related toxicity questions, especially as treatment is brought earlier and potentially given for longer durations. But in a front-line metastatic setting, durability of disease control matters enormously.
Therapeutic positioning and competitive implications
Enhertu's trajectory is strategic as much as clinical. It entered the market in 2019 in the third-line setting, then displaced prior standards in the second line after DESTINY-Breast03, expanded into HER2-low and HER2-ultralow biology, and has now reached the front line. That stepwise march validates a development playbook for high-performing ADCs: establish activity in refractory disease, then use randomized comparative trials to move steadily earlier. It also reinforces AstraZeneca and Daiichi Sankyo's decision to build an ADC-centered breast cancer franchise around a multibillion-dollar alliance originally valued at up to $6.9 billion.
Outlook
The next question is no longer whether trastuzumab deruxtecan belongs in HER2-positive breast cancer, but how broadly the ADC model can reshape sequencing. Movement into neoadjuvant and adjuvant settings is already becoming visible, which is where commercial upside and true standard-of-care transformation converge. For clinicians, the front-line approval offers a more potent option for durable disease control. For the broader ADC field, it sends a sharper message: the category is no longer defined by what it can rescue after failure, but by what it can replace at the top of the treatment paradigm.